Last reviewed · How we verify
Cardiology — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fludeoxyglucose F-18 | FLUDEOXYGLUCOSE | Downstate Clincl | Radioactive Diagnostic Agent [EPC] | 2020-01-01 | ||
| Fludeoxyglucose F-18 | F-18 | 3D Imaging Drug | Radioactive Diagnostic Agent [EPC] | 2015-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- 3D Imaging Drug · 1 drug in Cardiology
- Downstate Clincl · 1 drug in Cardiology
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cardiology:
- Cardiology treatment updates — RSS
- Cardiology treatment updates — Atom
- Cardiology treatment updates — JSON
Cite this brief
Drug Landscape (2026). Cardiology — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cardiology. Accessed 2026-06-10.
Related
- Cardiology full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing